# Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3

> **NCT07465926** · — · COMPLETED · sponsor: **Chung Shan Medical University** · enrollment: 451036 (actual)

## Conditions studied

- Cardiovascular-kidney-metabolic Syndrome
- Cardiovascular Disease Risk Factor
- Kidney Disease
- Type 2 Diabetes
- Obesity & Overweight

## Interventions

- **DRUG:** GLP-1 receptor agonist
- **DRUG:** SGLT2 inhibitor

## Key facts

- **NCT ID:** NCT07465926
- **Lead sponsor:** Chung Shan Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-01
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 451036 (ACTUAL)
- **Last updated:** 2026-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07465926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07465926, "Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07465926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*